Voriconazole contains the active substance voriconazole. Voriconazole is an antifungal medicine. It works by killing or stopping the growth of the fungi that cause infections.

It is used for the treatment of patients (adults and children aged 2 years and above) with:

• Invasive aspergillosis (a type of fungal infection due to Aspergillus sp)

• Candidaemia (another type of fungal infection due to Candida sp) in non-neutropenic patients (patients without abnormally low white blood cells count)

• Serious invasive Candida sp. infections when the fungus is resistant to fluconazole (another antifungal medicine)

• Serious fungal infections caused by Scedosporium sp. or Fusarium sp. (two different species of fungi)

Voriconazole is intended for patients with worsening, possibly life-threatening, fungal infections.

Voriconazole is also indicated for the prevention of fungal infections in high risk bone marrow transplant recipients.

Voriconazole can only be obtained with a prescription and should only be taken under the supervision of a doctor.

If you would like to see the Patient Information Leaflet (PIL) or Summary of Product Characteristics (SPC) for Voriconazole these can be found at the electronic Medicines Compendium (eMC).

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.

If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.